Supplementation of PQQ from pregnancy prevents MK-801-induced schizophrenia-like behaviors in mice.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE

Original Publication: Berlin, New York, Springer-Verlag.

Dizocilpine Maleate*/pharmacology ; Schizophrenia*/chemically induced ; Schizophrenia*/prevention & control; Animals ; Ataxia ; Dietary Supplements ; Female ; Male ; Memory Disorders ; Mice ; PQQ Cofactor/pharmacology ; Pregnancy ; Weight Gain

Rationale: At present, the research on the prevention of schizophrenia is still in its infancy. Pyrroloquinoline quinone (PQQ) has potential to treat psychological and neurological diseases including schizophrenia. However, the preventive effect of PQQ on schizophrenia remains unclear.
Objectives: In this study, we aimed to examine the preventive effect of supplementation of dietary PQQ from pregnancy or after birth on dizocilpine (MK-801)-induced schizophrenia-like behaviors in mice.
Results: Supplementation of dietary PQQ from pregnancy could effectively prevent MK-801-induced weight gain decrease, hyperlocomotion, stereotypical behavior, ataxia, exploratory activity decrease, social interaction disorder, memory deficit, and depression in mice. Supplementation of dietary PQQ after birth could effectively prevent MK-801-induced weight gain decrease, stereotypical behavior, ataxia, and memory deficit in mice. Female mice responded to a greater degree than males in preventing MK-801-induced weight gain decrease in both forms of PQQ supplementation. For mice that began PQQ supplementation after birth, females performed better than males in preventing MK-801-induced ataxia, memory deficit, and depression. For mice that began PQQ supplementation from pregnancy, males performed better than females in preventing MK-801-induced memory deficit. In vitro experiments indicated that PQQ supplementation in the earlier stage of life contributed to the growth of neurons and the development of neurites.
Conclusions: Our current study suggested that PQQ supplementation from pregnancy or postpartum could prevent some schizophrenia-like behaviors induced by MK-801 in mice. Our work supported the potential usage of dietary supplement of PQQ in preventing or alleviating symptoms associated with schizophrenia.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Adell A (2020) Brain NMDA receptors in schizophrenia and depression. Biomolecules 10:947. https://doi.org/10.3390/biom10060947. (PMID: 10.3390/biom100609477355879)
Aizenman E, Hartnett KA, Zhong C, Gallop PM, Rosenberg PA (1992) Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-D-aspartate receptor redox modulatory site. J Neurosci 12:2362–2369. https://doi.org/10.1523/jneurosci.12-06-02362.1992. (PMID: 10.1523/jneurosci.12-06-02362.199213189596575914)
Aizenman E, Jensen FE, Gallop PM, Rosenberg PA, Tang LH (1994) Further evidence that pyrroloquinoline quinone interacts with the receptor redox site in rat cortical neurons in vitro. Neurosci Lett 168:189–192. https://doi.org/10.1016/0304-3940(94)90447-2. (PMID: 10.1016/0304-3940(94)90447-27518062)
Alam C, Hoque MT, Sangha V, Bendayan R (2020) Nuclear respiratory factor 1 (NRF-1) upregulates the expression and function of reduced folate carrier (RFC) at the blood-brain barrier. FASEB J 34:10516–10530. https://doi.org/10.1096/fj.202000239RR. (PMID: 10.1096/fj.202000239RR32543769)
Bishop A, Gallop PM, Karnovsky ML (1998) Pyrroloquinoline quinone: a novel vitamin? Nutr Rev 56:287–293. https://doi.org/10.1111/j.1753-4887.1998.tb01661.x. (PMID: 10.1111/j.1753-4887.1998.tb01661.x9810806)
Bramon E, Murray RM (2001) A plausible model of schizophrenia must incorporate psychological and social as well as neuro developmental risk factors. Dialogues Clin Neurosci 3:243–256. https://doi.org/10.31887/DCNS.2001.3.4/ebramon. (PMID: 10.31887/DCNS.2001.3.4/ebramon220336793181665)
Bramon E, Walshe M, McDonald C, Martin B, Toulopoulou T, Wickham H, van Os J, Fearon P et al (2005) Dermatoglyphics and Schizophrenia: a meta-analysis and investigation of the impact of obstetric complications upon a-b ridge count. Schizophr Res 75:399–404. https://doi.org/10.1016/j.schres.2004.08.022. (PMID: 10.1016/j.schres.2004.08.02215885530)
Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC (2018) NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology 142:41–62. https://doi.org/10.1016/j.neuropharm.2017.11.045. (PMID: 10.1016/j.neuropharm.2017.11.04529196183)
Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, DeLucia M, Duffy R et al (2016) The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry 77:764–771. https://doi.org/10.4088/JCP.15m10278. (PMID: 10.4088/JCP.15m1027827135986)
Correll CU, Schooler NR (2020) Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat 16:519–534. https://doi.org/10.2147/NDT.S225643. (PMID: 10.2147/NDT.S225643321100267041437)
de Oliveira RV, Dall’Igna OP, Tort AB, Schuh JF, Neto PF, Santos Gomes MW, Souza DO, Lara DR (2005) Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. Behav Pharmacol 16:79–84. https://doi.org/10.1097/00008877-200503000-00002. (PMID: 10.1097/00008877-200503000-0000215767842)
Efsa Panel on Dietetic Products N, Allergies TD, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M et al (2017) Safety of pyrroloquinoline quinone disodium salt as a novel food pursuant to Regulation (EC) No 258/97. EFSA J 15:e05058. https://doi.org/10.2903/j.efsa.2017.5058. (PMID: 10.2903/j.efsa.2017.5058)
Estes ML, McAllister AK (2016) Maternal immune activation: implications for neuropsychiatric disorders. Science 353:772–777. https://doi.org/10.1126/science.aag3194. (PMID: 10.1126/science.aag3194275401645650490)
Fernando P, Sommer IEC, Hasan A (2020) Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia? Curr Opin Psychiatry 33:192–199. https://doi.org/10.1097/YCO.0000000000000597. (PMID: 10.1097/YCO.000000000000059732068570)
Fujita Y, Ishima T, Hashimoto K (2016) Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation. Sci Rep 6:37261. https://doi.org/10.1038/srep37261. (PMID: 10.1038/srep37261278532415112512)
Gallop PM, Paz MA, Flückiger R, Kagan HM (1989) PQQ, the elusive coenzyme. Trends Biochem Sci 14:343–346. https://doi.org/10.1016/0968-0004(89)90169-2. (PMID: 10.1016/0968-0004(89)90169-22572081)
Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R et al (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21–27. https://doi.org/10.1001/archpsyc.56.1.21. (PMID: 10.1001/archpsyc.56.1.219892252)
Han M, Zhang JC, Yao W, Yang C, Ishima T, Ren Q, Ma M, Dong C et al (2016) Intake of 7,8-dihydroxyflavone during juvenile and adolescent stages prevents onset of psychosis in adult offspring after maternal immune activation. Sci Rep 6:36087. https://doi.org/10.1038/srep36087. (PMID: 10.1038/srep36087278241195099694)
Hashimoto K (2019) Recent advances in the early intervention in schizophrenia: future direction from preclinical findings. Curr Psychiatry Rep 21:75. https://doi.org/10.1007/s11920-019-1063-7. (PMID: 10.1007/s11920-019-1063-731278495)
Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57:577–585. https://doi.org/10.1016/j.biopsych.2004.12.037. (PMID: 10.1016/j.biopsych.2004.12.03715780844)
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610–617. https://doi.org/10.1192/bjp.169.5.610. (PMID: 10.1192/bjp.169.5.6108932891)
Hulshoff Pol HE, Hoek HW, Susser E, Brown AS, Dingemans A, Schnack HG, van Haren NE, Pereira Ramos LM et al (2000) Prenatal exposure to famine and brain morphology in schizophrenia. Am J Psychiatry 157:1170–1172. https://doi.org/10.1176/appi.ajp.157.7.1170. (PMID: 10.1176/appi.ajp.157.7.117010873931)
Itoh Y, Hine K, Miura H, Uetake T, Nakano M, Takemura N, Sakatani K (2016) Effect of the antioxidant supplement pyrroloquinoline quinone disodium salt (BioPQQ) on cognitive functions. Adv Exp Med Biol 876:319–325. https://doi.org/10.1007/978-1-4939-3023-4_40. (PMID: 10.1007/978-1-4939-3023-4_4026782228)
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F et al (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858. https://doi.org/10.1016/s0140-6736(18)32279-7. (PMID: 10.1016/s0140-6736(18)32279-7)
Jentsch J (1999) The neuropsychopharmacology of phencyclidine from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–225. https://doi.org/10.1016/s0893-133x(98)00060-8. (PMID: 10.1016/s0893-133x(98)00060-810063482)
Kishi T, Matsuda Y, Iwata N (2017) Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology 234:2113–2125. https://doi.org/10.1007/s00213-017-4616-7. (PMID: 10.1007/s00213-017-4616-728508107)
Koek W, Woods JH, Winger GD (1988) MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245:969–974. https://doi.org/10.1007/BF01062140. (PMID: 10.1007/BF010621402838610)
Lange B, Mueller JK, Leweke FM, Bumb JM (2017) How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review. Expert Opin Pharmacother 18:351–362. https://doi.org/10.1080/14656566.2017.1288722. (PMID: 10.1080/14656566.2017.128872228129701)
Lewine R, Hart M (2020) Schizophrenia spectrum and other psychotic disorders. Handb Clin Neurol 175:315–333. https://doi.org/10.1016/B978-0-444-64123-6.00022-9. (PMID: 10.1016/B978-0-444-64123-6.00022-933008535)
Lieberman JA, Small SA, Girgis RR (2019) Early detection and preventive intervention in schizophrenia: from fantasy to reality. Am J Psychiatry 176:794–810. https://doi.org/10.1176/appi.ajp.2019.19080865. (PMID: 10.1176/appi.ajp.2019.1908086531569988)
Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR (1992) Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149:1183–1188. https://doi.org/10.1176/ajp.149.9.1183. (PMID: 10.1176/ajp.149.9.11831503130)
Ma M, Ren Q, Yang J, Zhang K, Xiong Z, Ishima T, Pu Y, Hwang SH et al (2019) Key role of soluble epoxide hydrolase in the neurodevelopmental disorders of offspring after maternal immune activation. Proc Natl Acad Sci U S A 116:7083–7088. https://doi.org/10.1073/pnas.1819234116. (PMID: 10.1073/pnas.1819234116308906456452650)
Marder SR, Cannon TD (2019) Schizophrenia. N Engl J Med 381:1753–1761. https://doi.org/10.1056/NEJMra1808803. (PMID: 10.1056/NEJMra180880331665579)
McCutcheon RA, Reis Marques T, Howes OD (2020) Schizophrenia-an overview. JAMA. Psychiatry 77:201–210. https://doi.org/10.1001/jamapsychiatry.2019.3360. (PMID: 10.1001/jamapsychiatry.2019.3360)
McGrath JJ, Feron FP, Burne TH, Mackay-Sim A, Eyles DW (2003) The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Ann Med 35:86–93. https://doi.org/10.1080/07853890310010005. (PMID: 10.1080/0785389031001000512795338)
Min Z, Wang L, Jin J, Wang X, Zhu B, Chen H, Cheng Y (2014) Pyrroloquinoline quinone induces cancer cell apoptosis via mitochondrial-dependent pathway and down-regulating cellular Bcl-2 protein expression. J Cancer 5:609–624. https://doi.org/10.7150/jca.9002. (PMID: 10.7150/jca.9002251616994143536)
Misra HS, Rajpurohit YS, Khairnar NP (2012) Pyrroloquinoline-quinone and its versatile roles in biological processes. J Biosci 37:313–325. https://doi.org/10.1007/s12038-012-9195-5. (PMID: 10.1007/s12038-012-9195-522581337)
Mitchell AE, Jones AD, Mercer RS, Rucker RB (1999) Characterization of pyrroloquinoline quinone amino acid derivatives by electrospray ionization mass spectrometry and detection in human milk. Anal Biochem 269:317–325. https://doi.org/10.1006/abio.1999.4039. (PMID: 10.1006/abio.1999.403910222004)
Murase K, Hattori A, Kohno M, Hayashi K (1993) Stimulation of nerve growth factor synthesis/secretion in mouse astroglial cells by coenzymes. Biochem Mol Biol Int 30:615–621. https://doi.org/10.1016/0305-1978(93)90067-2. (PMID: 10.1016/0305-1978(93)90067-28401318)
Ninan I, Kulkarni SK (1998) 5-HT2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion. Eur J Pharmacol 358:111–116. https://doi.org/10.1016/s0014-2999(98)00591-3. (PMID: 10.1016/s0014-2999(98)00591-39808259)
Ohwada K, Takeda H, Yamazaki M, Isogai H, Nakano M, Shimomura M, Fukui K, Urano S (2008) Pyrroloquinoline quinone (PQQ) prevents cognitive deficit caused by oxidative stress in rats. J Clin Biochem Nutr 42:29–34. https://doi.org/10.3164/jcbn.2008005. (PMID: 10.3164/jcbn.200800518231627)
Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383–400. https://doi.org/10.1038/nrn3504. (PMID: 10.1038/nrn350423686171)
Peng Y, Xu D, Mao S, Zhou X (2020) Neurotoxicity and apoptosis induced by pyrroloquinoline quinone and its ester derivative on primary cortical neurons. Neurotoxicology 78:47–56. https://doi.org/10.1016/j.neuro.2020.02.005. (PMID: 10.1016/j.neuro.2020.02.00532068067)
Perkins DO, Gu H, Boteva K, Lieberman JA (2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162:1785–1804. https://doi.org/10.1176/appi.ajp.162.10.1785. (PMID: 10.1176/appi.ajp.162.10.178516199825)
Rogoz Z, Wasik A, Lorenc-Koci E (2018) Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. Pharmacol Rep 70:623–630. https://doi.org/10.1016/j.pharep.2018.02.022. (PMID: 10.1016/j.pharep.2018.02.02229885435)
Rucker R, Chowanadisai W, Nakano M (2009) Potential physiological importance of pyrroloquinoline quinone. Altern Med Rev 14:268–277. https://doi.org/10.1007/978-3-0348-8397-9_10. (PMID: 10.1007/978-3-0348-8397-9_1019803551)
Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141. https://doi.org/10.1371/journal.pmed.0020141. (PMID: 10.1371/journal.pmed.0020141159164721140952)
Salisbury SA, Forrest HS, Cruse WB, Kennard O (1979) A novel coenzyme from bacterial primary alcohol dehydrogenases. Nature 280:843–844. https://doi.org/10.1038/280843a0. (PMID: 10.1038/280843a0471057)
Santillan-Urquiza MA, Herrera-Ruiz M, Zamilpa A, Jimenez-Ferrer E, Roman-Ramos R, Alegria-Herrera EY, Tortoriello J (2019) Galphimia glauca and natural galphimines block schizophrenia-like symptoms induced with apomorphine and MK-801 in mice. Evid Based Complement Alternat Med 2019:8404258. https://doi.org/10.1155/2019/8404258. (PMID: 10.1155/2019/8404258314281766679897)
Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M (2018) Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: a double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 82:289–296. https://doi.org/10.1016/j.pnpbp.2017.11.001. (PMID: 10.1016/j.pnpbp.2017.11.00129126981)
Steinberg FM, Gershwin ME, Rucker RB (1994) Dietary pyrroloquinoline quinone: growth and immune response in BALB/c mice. J Nutr 124:744–753. https://doi.org/10.1093/jn/124.5.744. (PMID: 10.1093/jn/124.5.7448169668)
Sullivan PF, Kendler KS, Neale MC (2003) Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 60:1187–1192. https://doi.org/10.1001/archpsyc.60.12.1187. (PMID: 10.1001/archpsyc.60.12.118714662550)
Tao R, Karliner JS, Simonis U, Zheng J, Zhang J, Honbo N, Alano CC (2007) Pyrroloquinoline quinone preserves mitochondrial function and prevents oxidative injury in adult rat cardiac myocytes. Biochem Biophys Res Commun 363:257–262. https://doi.org/10.1016/j.bbrc.2007.08.041. (PMID: 10.1016/j.bbrc.2007.08.041178809222844438)
Thorup A, Albert N, Bertelsen M, Petersen L, Jeppesen P, Le Quack P, Krarup G, Jorgensen P et al (2014) Gender differences in first-episode psychosis at 5-year follow-up–two different courses of disease? Results from the OPUS study at 5-year follow-up. Eur Psychiatry 29:44–51. https://doi.org/10.1016/j.eurpsy.2012.11.005. (PMID: 10.1016/j.eurpsy.2012.11.00523394824)
Tiihonen J, Koskuvi M, Storvik M, Hyotylainen I, Gao Y, Puttonen KA, Giniatullina R, Poguzhelskaya E et al (2019) Sex-specific transcriptional and proteomic signatures in schizophrenia. Nat Commun 10:3933. https://doi.org/10.1038/s41467-019-11797-3. (PMID: 10.1038/s41467-019-11797-3314776936718673)
Tsai GE, Yang P, Chang YC, Chong MY (2006) D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 59:230–234. https://doi.org/10.1016/j.biopsych.2005.06.032. (PMID: 10.1016/j.biopsych.2005.06.03216154544)
Tsuang MT, Stone WS, Auster TL (2010) Prevention of schizophrenia. Expert Rev Neurother 10:1165–1174. https://doi.org/10.1586/ern.10.87. (PMID: 10.1586/ern.10.8720586696)
Ueno H, Suemitsu S, Murakami S, Kitamura N, Wani K, Takahashi Y, Matsumoto Y, Okamoto M et al (2019) Behavioural effects of inhalation exposure to dizocilpine (MK-801) in mice. Biomed Pharmacother 117:109038. https://doi.org/10.1016/j.biopha.2019.109038. (PMID: 10.1016/j.biopha.2019.10903831177060)
Uno Y, Coyle JT (2019) Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci 73:204–215. https://doi.org/10.1111/pcn.12823. (PMID: 10.1111/pcn.1282330666759)
Xiong XH, Zhao Y, Ge X, Yuan SJ, Wang JH, Zhi JJ, Yang YX, Du BH et al (2011) Production and radioprotective effects of pyrroloquinoline quinone. Int J Mol Sci 12:8913–8923. https://doi.org/10.3390/ijms12128913. (PMID: 10.3390/ijms12128913222721113257108)
Xu MQ, Sun WS, Liu BX, Feng GY, Yu L, Yang L, He G, Sham P et al (2009) Prenatal malnutrition and adult schizophrenia: further evidence from the 1959–1961 Chinese famine. Schizophr Bull 35:568–576. https://doi.org/10.1093/schbul/sbn168. (PMID: 10.1093/schbul/sbn168191553442669578)
Zhao J, Liu X, Huo C, Zhao T, Ye H (2018) Abnormalities in prefrontal cortical gene expression profiles relevant to schizophrenia in MK-801-exposed C57BL/6 mice. Neuroscience 390:60–78. https://doi.org/10.1016/j.neuroscience.2018.07.046. (PMID: 10.1016/j.neuroscience.2018.07.04630102956)
Zhou XQ, Chen QC, Hu XD, Mao SS, Kong YY (2014) Pyrroloquinoline quinone prevents MK-801-induced stereotypical behavior and cognitive deficits in mice. Behav Brain Res 258:153–159. https://doi.org/10.1016/j.bbr.2013.10.025. (PMID: 10.1016/j.bbr.2013.10.02524149067)
Zhou XQ, Yao ZW, Peng Y, Mao SS, Xu D, Qin XF, Zhang RJ (2018) PQQ ameliorates D-galactose induced cognitive impairments by reducing glutamate neurotoxicity via the GSK-3beta/Akt signaling pathway in mouse. Sci Rep 8:8894. https://doi.org/10.1038/s41598-018-26962-9. (PMID: 10.1038/s41598-018-26962-9298918415995849)

81803586 national natural science foundation of china; 81371590 national natural science foundation of china

Keywords: MK-801; NMDA receptor; Prevention; Pyrroloquinoline quinone; Schizophrenia

6LR8C1B66Q (Dizocilpine Maleate)
72909-34-3 (PQQ Cofactor)

Date Created: 20220316 Date Completed: 20220621 Latest Revision: 20220621

20250114

10.1007/s00213-022-06113-9

35294602